The Correlation of Mouse Double Minute 4 (MDM4) Polymorphisms (rs4245739, rs1563828, rs11801299, rs10900598, and rs1380576) with Cancer Susceptibility: A Meta-Analysis.


Journal

Medical science monitor : international medical journal of experimental and clinical research
ISSN: 1643-3750
Titre abrégé: Med Sci Monit
Pays: United States
ID NLM: 9609063

Informations de publication

Date de publication:
29 Mar 2022
Historique:
entrez: 29 3 2022
pubmed: 30 3 2022
medline: 8 4 2022
Statut: epublish

Résumé

BACKGROUND Mouse double minute 4 (MDM4) has been extensively investigated as a negative regulator of P53, its negative feedback loop, and the effect of its genetic polymorphisms on cancers. However, many studies showed varying and even conflicting results. Therefore, we employed meta-analysis to further assess the intensity of the connection between MDM4 polymorphisms and malignancies. MATERIAL AND METHODS We searched eligible articles in 5 databases (Cochrane Library, PubMed, Web of Science, Wan Fang Database, and China National Knowledge Infrastructure) up to August 2021. Odds ratios (ORs) and 95% confidence intervals (CIs) were utilized to probe the correlation of 5 MDM4 polymorphisms (rs4245739, rs1563828, rs11801299, rs10900598, and rs1380576) with carcinomas. We employed meta-regression and subgroup analysis to probe for sources of heterogeneity; Funnel plots, Begg's test, and Egger's test were used to evaluate publication bias. Sensitivity analysis was applied to assess the stability of the study. RESULTS Twenty-two studies, comprising 77 reports with 29 853 cases and 72 045 controls, were included in our meta-analysis. We found that rs4245739 polymorphism was a factor in reducing overall cancer susceptibility (dominant model, OR=0.85, 95% CI=0.76-0.95; heterozygous model, OR=0.86, 95% CI=0.78-0.96; additive model, OR=0.87, 95% CI=0.79-0.95), especially in Asian populations, and it also reduces the risk for esophageal squamous cell carcinoma (ESCC). The remaining 4 SNPs were not associated with cancers. CONCLUSIONS The rs4245739 polymorphism might reduce the risk of malignancies, especially in Asian populations, and it is a risk-reducing factor for ESCC incidence. However, rs1563828, rs11801299, rs10900598, and rs1380576 are not relevant to cancer susceptibility.

Identifiants

pubmed: 35347102
pii: 935671
doi: 10.12659/MSM.935671
pmc: PMC8976448
doi:

Substances chimiques

Cell Cycle Proteins 0
MDM4 protein, human 0
Nuclear Proteins 0
Proto-Oncogene Proteins 0

Types de publication

Journal Article Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Pagination

e935671

Références

Clin Lab. 2016 Jul 01;62(7):1303-1308
pubmed: 28164646
EMBO J. 1996 Oct 1;15(19):5349-57
pubmed: 8895579
PLoS One. 2013 May 28;8(5):e64331
pubmed: 23724042
PLoS One. 2014 Sep 09;9(9):e107047
pubmed: 25203442
Pathol Oncol Res. 2020 Oct;26(4):2409-2423
pubmed: 32556890
Med Sci Monit. 2019 Feb 18;25:1307-1313
pubmed: 30774116
Clin Cancer Res. 2016 Feb 15;22(4):868-76
pubmed: 26459177
Nat Genet. 2013 Apr;45(4):392-8, 398e1-2
pubmed: 23535733
Chem Soc Rev. 2020 Oct 5;49(19):6995-7014
pubmed: 32869798
Pharmacogenet Genomics. 2011 Jul;21(7):388-96
pubmed: 21540763
Int J Biol Markers. 2021 Jun;36(2):17246008211033874
pubmed: 34347554
Lancet Oncol. 2012 Nov;13(11):1133-40
pubmed: 23084521
Genes Cancer. 2011 Apr;2(4):466-74
pubmed: 21779514
Front Oncol. 2020 Aug 05;10:1389
pubmed: 32850448
Cancer Epidemiol. 2019 Feb;58:153-159
pubmed: 30597480
J Med Chem. 2021 Aug 12;64(15):10621-10640
pubmed: 34286973
J Epidemiol Glob Health. 2019 Dec;9(4):217-222
pubmed: 31854162
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Nat Rev Cancer. 2009 Nov;9(11):821-9
pubmed: 19776747
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Breast Cancer Res Treat. 2013 Jul;140(1):151-7
pubmed: 23793604
Int J Biol Markers. 2017 Mar 2;32(1):e62-e67
pubmed: 27646776
Tumour Biol. 2016 Aug;37(8):10697-702
pubmed: 26867771
Onco Targets Ther. 2019 Apr 16;12:2903-2910
pubmed: 31289443
Clin Breast Cancer. 2018 Oct;18(5):e883-e891
pubmed: 29439926
Pharmgenomics Pers Med. 2020 Nov 26;13:673-678
pubmed: 33273845
Zhonghua Wai Ke Za Zhi. 2012 Jan 1;50(1):53-6
pubmed: 22490292
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643228
Oncotarget. 2016 Nov 1;7(44):71718-71726
pubmed: 27687591
PLoS One. 2015 Aug 14;10(8):e0135647
pubmed: 26274820
Melanoma Res. 2014 Jun;24(3):190-7
pubmed: 24625390
Cancer Med. 2015 Dec;4(12):1901-7
pubmed: 26471763
Oncol Lett. 2012 May;3(5):1115-1118
pubmed: 22783402
Nat Rev Cancer. 2013 Feb;13(2):83-96
pubmed: 23303139
J Clin Med. 2020 Jun 01;9(6):
pubmed: 32492903
Oncotarget. 2016 Nov 8;7(45):73935-73944
pubmed: 27738340
Med Oncol. 2015 Jan;32(1):401
pubmed: 25479941
Cancer. 2012 Mar 15;118(6):1684-92
pubmed: 21823114
Oncotarget. 2017 Mar 21;8(12):19547-19555
pubmed: 28099948
Oncotarget. 2016 Aug 23;7(34):55611-55623
pubmed: 27742919
Cancer Cell. 2014 Mar 17;25(3):304-17
pubmed: 24651012
Asian Pac J Cancer Prev. ;18(4):1133-1138
pubmed: 28547953
Med Sci Monit. 2015 Jan 16;21:213-8
pubmed: 25600314

Auteurs

Jian Chen (J)

Department of General Surgery, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).

Xudong Li (X)

Department of Surgery,, Wannian Maternal and Child Health Hospital, Shangrao, Jiangxi, China (mainland).

Ruihao Liu (R)

Department of General Surgery, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).

Yufen Xie (Y)

Department of General Surgery, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).

Zhigao Liu (Z)

Department of General Surgery, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).

Haiwei Xiong (H)

Department of General Surgery, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).

Yingliang Li (Y)

Department of General Surgery, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH